Clinical Trials

Sponsor: Seattle Genetics, Inc.

Sponsor Study ID: SEA-CD70

Study Title: A Phase 1 Study of SEA CD70 in Myeloid Malignancies

NCT Number: NCT04227847

Phase: I

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Myeloid and Monocytic Leukemia

Study Objectives: This is a phase 1, open-label, multicenter, dose-escalation, and cohort expansion study designed to evaluate the safety, tolerability, PK, and antitumor activity of SEA-CD70 in adults with myeloid malignancies. The study will be conducted in up to 3 parts. Part A is a dose escalation cohort designed to identify the MTD or recommended expansion dose of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part B is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part C is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory AML.



For more information about the trial above please contact the study team:

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)